NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression

NCT03368677

Active Not RecruitingN/A

Sponsor: Turku University Hospital

Conditions: Multiple Sclerosis

Countries: Finland

To evaluate the effect of teriflunomide treatment on microglial activation in late stage multiple sclerosis.

Eligibility overview

Sex: ALL

Age: 40 Years to 55 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Signing the consent form
* Having used teriflunomide treatment for at least 6 months
* 40-55 years of age at the time of signing the research consent form
* MS diagnosis in accordance with either the Poser or McDonald criteria
* EDSS 2-6.5
* Clear lesion load in brain MRI (\> 9 T2 lesion)

Exclusion Criteria:

* Patients suffering from another brain disease of in addition to multiple sclerosis
* Steroid treatment 4 weeks prior to the scan
* Significant pathology in the MRI scan other than MS-related lesions
* Patients suffering from claustrophobia or panic disorder, or patients who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
* Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
* Severe hepatic impairment
* Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with teriflunomide and thereafter as long as its plasma levels are above 0.02 mg/l.

Locations (1)

Turku, Southwest Finland, Finland